{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:19Z","timestamp":1790806099246,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA-DC000087"],"award-info":[{"award-number":["ZIA-DC000087"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Intramural Funding"],"award-info":[{"award-number":["Intramural Funding"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0603-3","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:04:30Z","timestamp":1556895870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis"],"prefix":"10.1136","volume":"7","author":[{"given":"Clint T.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Norberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Kovalovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Clavijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"603_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.virusres.2016.12.017","volume":"231","author":"N Egawa","year":"2017","unstructured":"Egawa N, Doorbar J. The low-risk papillomaviruses. Virus Res. 2017;231:119\u201327.","journal-title":"Virus Res"},{"issue":"1","key":"603_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00005537-200101000-00011","volume":"111","author":"CS Derkay","year":"2001","unstructured":"Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111(1):57\u201369.","journal-title":"Laryngoscope."},{"key":"603_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.rmed.2017.03.030","volume":"126","author":"HR Fortes","year":"2017","unstructured":"Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med. 2017;126:116\u201321.","journal-title":"Respir Med"},{"issue":"8","key":"603_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2886","volume":"10","author":"CA Moody","year":"2010","unstructured":"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"603_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamaoto.2016.2724","volume":"143","author":"EC Tatar","year":"2017","unstructured":"Tatar EC, Kupfer RA, Barry JY, Allen CT, Merati AL. Office-based vs traditional operating room Management of Recurrent Respiratory Papillomatosis: impact of patient characteristics and disease severity. JAMA Otolaryngol Head Neck Surg. 2017;143(1):55\u20139.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"7","key":"603_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1097\/MLG.0b013e31816a7135","volume":"118","author":"CS Derkay","year":"2008","unstructured":"Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236\u201347.","journal-title":"Laryngoscope"},{"issue":"7","key":"603_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJM198808183190704","volume":"319","author":"GB Healy","year":"1988","unstructured":"Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med. 1988;319(7):401\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"603_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446\u201353.","journal-title":"Lancet Oncol"},{"key":"603_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.critrevonc.2018.06.006","volume":"129","author":"F Felice De","year":"2018","unstructured":"De Felice F, Marchetti C, Palaia I, Ostuni R, Muzii L, Tombolini V, et al. Immune check-point in cervical cancer. Crit Rev Oncol Hematol. 2018;129:40\u20133.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"603_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"key":"603_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","volume":"56","author":"M Rao","year":"2017","unstructured":"Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017;56:221\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"603_CR12","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1002\/lary.26847","volume":"128","author":"J Ahn","year":"2018","unstructured":"Ahn J, Bishop JA, Roden RBS, Allen CT, Best SRA. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis. Laryngoscope. 2018;128(1):E27\u201332.","journal-title":"Laryngoscope."},{"issue":"10","key":"603_CR13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"1","key":"603_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51\u201364.","journal-title":"Lancet Oncol"},{"issue":"6","key":"603_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/00005537-199806000-00026","volume":"108","author":"CS Derkay","year":"1998","unstructured":"Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope. 1998;108(6):935\u20137.","journal-title":"Laryngoscope."},{"issue":"9","key":"603_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1097\/00005537-200409000-00009","volume":"114","author":"CA Rosen","year":"2004","unstructured":"Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope. 2004;114(9):1549\u201356.","journal-title":"Laryngoscope."},{"issue":"4","key":"603_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","volume":"26","author":"ME Dudley","year":"2003","unstructured":"Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332\u201342.","journal-title":"J Immunother"},{"issue":"8","key":"603_CR18","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"7","key":"603_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/000348940811700702","volume":"117","author":"JS McMurray","year":"2008","unstructured":"McMurray JS, Connor N, Ford CN. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol. 2008;117(7):477\u201383.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"603_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","volume":"18","author":"JL Gulley","year":"2017","unstructured":"Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):599\u2013610.","journal-title":"Lancet Oncol."},{"issue":"10","key":"603_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.","journal-title":"J Clin Oncol"},{"issue":"7","key":"603_CR22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"11 Pt 2 Suppl 1","key":"603_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.mlg.000148224.83491.0f","volume":"114","author":"BJ Wiatrak","year":"2004","unstructured":"Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope. 2004;114(11 Pt 2 Suppl 104):1\u201323.","journal-title":"Laryngoscope."},{"issue":"1","key":"603_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcv.2006.09.008","volume":"38","author":"L Marco De","year":"2007","unstructured":"De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F. Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J Clin Virol. 2007;38(1):7\u201313.","journal-title":"J Clin Virol"},{"issue":"11","key":"603_CR25","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1097\/01.mlg.0000147918.81733.49","volume":"114","author":"PM Reidy","year":"2004","unstructured":"Reidy PM, Dedo HH, Rabah R, Field JB, Mathog RH, Gregoire L, et al. Integration of human papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope. 2004;114(11):1906\u20139.","journal-title":"Laryngoscope"},{"issue":"2","key":"603_CR26","doi-asserted-by":"publisher","first-page":"e57207","DOI":"10.1371\/journal.pone.0057207","volume":"8","author":"CU Huebbers","year":"2013","unstructured":"Huebbers CU, Preuss SF, Kolligs J, Vent J, Stenner M, Wieland U, et al. Integration of HPV6 and downregulation of AKR1C3 expression mark malignant transformation in a patient with juvenile-onset laryngeal papillomatosis. PLoS One. 2013;8(2):e57207.","journal-title":"PLoS One"},{"issue":"1","key":"603_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56\u201371.","journal-title":"Immunol Rev"},{"issue":"6334","key":"603_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","volume":"356","author":"S Stevanovic","year":"2017","unstructured":"Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200\u20135.","journal-title":"Science."},{"issue":"7528","key":"603_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature."},{"issue":"3","key":"603_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/clim.1999.4784","volume":"93","author":"VR Bonagura","year":"1999","unstructured":"Bonagura VR, Hatam L, DeVoti J, Zeng F, Steinberg BM. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1\/T(H)2 cytokine imbalance. Clin Immunol. 1999;93(3):302\u201311.","journal-title":"Clin Immunol"},{"issue":"6\u20137","key":"603_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0463.2010.02617.x","volume":"118","author":"VR Bonagura","year":"2010","unstructured":"Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS. 2010;118(6\u20137):455\u201370.","journal-title":"APMIS."},{"issue":"1","key":"603_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/CDLI.7.1.79-85.2000","volume":"7","author":"A Vambutas","year":"2000","unstructured":"Vambutas A, Bonagura VR, Steinberg BM. Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin Diagn Lab Immunol. 2000;7(1):79\u201385.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"7","key":"603_CR33","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-11-2941","volume":"18","author":"LJ Hatam","year":"2012","unstructured":"Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM, et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1\/PD-L1\/L2 expression. Clin Cancer Res. 2012;18(7):1925\u201335.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"603_CR34","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1158\/0008-5472.CAN-14-0602-T","volume":"74","author":"C Levovitz","year":"2014","unstructured":"Levovitz C, Chen D, Ivansson E, Gyllensten U, Finnigan JP, Alshawish S, et al. TGFbeta receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res. 2014;74(23):6833\u201344.","journal-title":"Cancer Res"},{"issue":"2","key":"603_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague J. TGFbeta in cancer. Cell. 2008;134(2):215\u201330.","journal-title":"Cell."},{"issue":"3","key":"603_CR36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162\u201374.","journal-title":"Nat Rev Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0603-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T05:47:50Z","timestamp":1607579270000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0603-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0603-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the National Cancer Institute (NCI) Institution Review Board and the National Institutes of Health Clinical Center (NCT02859454), and informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Full consent for the publication of patient demographics and endoscopic images was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"119"}}